A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: This was a strategic business decision. There were no safety concerns contributing to this decision.
    • Eligibility criteria expanded, about 30 words
    • Site details revised at 1 of 54 sites
  2. Primary and study completion pushed from Jul 22, 2026 to Sep 30, 2026v34
  3. Study Status, Referencesv33
  4. Re-verified, no change to tracked fieldsv32
  5. Primary and study completion dates: Jan 30, 2027 to Jul 22, 2026v31
Show 29 earlier versionsHide 29 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 314 to confirmed 73
    • Study sites: 91 to 54
    v30
  2. Site details revised at 2 of 91 sitesv29
  3. Site details revised at 3 of 91 sitesv28
  4. Study sites: 73 to 91v27
  5. Study sites: 78 to 73v26
  6. Study sites: 79 to 78v25
  7. Study sites: 78 to 79v24
  8. Site details revised at 1 of 78 sitesv23
  9. Site details revised at 1 of 78 sitesv22
  10. Site details revised at 1 of 78 sitesv21
  11. Study sites: 87 to 78v20
  12. Site details revised at 2 of 87 sitesv19
  13. Study sites: 88 to 87v18
  14. Study sites: 83 to 88v17
  15. Site details revised at 4 of 83 sitesv16
  16. Site details revised at 1 of 83 sitesv15
  17. Site details revised at 4 of 83 sitesv14
  18. Study sites: 84 to 83v13
  19. Study sites: 83 to 84v12
  20. Site details revised at 3 of 83 sitesv11
  21. Study sites: 92 to 83v10
  22. Site details revised at 2 of 92 sitesv9
  23. Study sites revised (92)v8
  24. Start date changed from estimate of Nov 14, 2023 to Oct 30, 2023v7
  25. Start date: Sep 29, 2023 to Nov 14, 2023
    • Site details revised at 13 of 92 sites
    v6
  26. Study sites: 91 to 92v5
  27. Start date: Aug 25, 2023 to Sep 29, 2023
    • Study sites: 82 to 91
    v4
  28. Study sites: 80 to 82v3
  29. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date: Jun 30, 2023 to Aug 25, 2023
    • Study sites: 0 to 80
    • Primary and study completion dates: Apr 20, 2027 to Jan 30, 2027
    • Eligibility criteria expanded, about 3 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 7 trials at risk
Lung Cancer
4,803 trials monitored
See 272 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,087 trials monitored
See 179 trials at risk
Liver Cancer
1,603 trials monitored
See 70 trials at risk
and 2 more diseases
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
Trial Details
NCT Number NCT05879822
Lead Sponsor Incyte Corporation
Conditions
(from sponsor)		 Advanced Solid Tumor
Related terms Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma
Enrollment 73 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov